InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,902.40
(
0.02%
)
Post# of 252428
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

apljack

Send PM Follow Ignore
Followers 6
Posts 703
Boards Moderated 0
Alias Born 09/23/2006

apljack

Re: DewDiligence post# 68562

Friday, 11/14/2008 5:50:41 PM

Friday, November 14, 2008 5:50:41 PM

Post# of 252428
Co.'s without the money to reach the finish line:

I am not a balance sheet expert but actually think that JAV can make it through the NDA for Dyloject in the US, but doubt they will be able to for Ereska without a partner. UK sales of Dyloject were slightly ahead of prjections for their first full quarter and hospital formulary adoption is also ahead of schedule with reorders ahead of schedule. That said, the revenue stream will still be too little too late.

Co.'s that have NO chance to make it, IMO, include COR (CX1717) and PPHM (Bavituximab), but neither of these have reached phase 3 yet.

(Big sigh!) Clearly no early retirement for me.

aj
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up